A patient portrayal of a smiling woman on her phone,with a bright, green field behind her A patient portrayal of a smiling woman on her phone,with a bright, green field behind her

SYLVANT SUPPORT

Financial Assistance

Patient portrayal

The personalized support you need to start SYLVANT

Recordati Access, Resources, and Engagement - Patient Support Program logo

is a patient support program designed to make it easier for you to access and stay on treatment.

Support may include:
Insurance Support
Financial Assistance
Insurance Support
Insurance support icon
  • Insurance verification–determining whether your insurance company will cover SYLVANT and help with understanding your insurance benefits for SYLVANT
  • Prior authorizations/appeals–working with your doctor’s office and insurance company if additional approvals are needed
Financial Assistance
Financial Assistance icon
  • Co-pay assistance–getting SYLVANT for $5 per infusion* if you are an eligible commercially insured patient. For patients who are not eligible for co-pay support or who need additional assistance, R.A.R.E. can help connect you to other possible sources of funding
  • Patient Assistance Program (PAP)–coordinating access for SYLVANT if you are an eligible patient who doesn’t have insurance or is underinsured
  • Additional assistance–directing you to outside assistance if appropriate

Eligible patients pay $5 per infusion*

* Restrictions, limitations, and/or eligibility requirements apply.

Keep this information handy with our R.A.R.E. patient support program flyer 
A patient portrayal of a smiling man looking at his phone
Patient portrayal

Contact the R.A.R.E. Patient Support Program:

Monday–Friday, 9 AM to 6 PM ET: 1-855-299-8844

Get personalized support

Our patient liaison is ready to help you every step of the way.

IL-6, interleukin-6; R.A.R.E., Recordati Access, Resources, and Engagement.

What is SYLVANT?

SYLVANT® (siltuximab) is a prescription medicine used to treat people with multicentric Castleman’s disease (MCD) who do not have human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8) infection. It is not known if SYLVANT is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Who should not receive SYLVANT?

Do not receive SYLVANT if you have had a severe allergic reaction to siltuximab or any of the ingredients in SYLVANT. See the Patient Information leaflet for SYLVANT for a complete list of ingredients.

Before starting SYLVANT, tell your healthcare provider (HCP) about all of your medical conditions, including if you:

  • have an infection. You should not receive SYLVANT if you have a severe infection.
  • have had a recent vaccination or are scheduled to receive any vaccinations. You should not receive a live vaccine during your treatment with SYLVANT.
  • have or have had any stomach or bowel (intestine) problems, such as diverticulitis or ulcers. Tell your healthcare provider if you have pain in your stomach area.
  • are pregnant or plan to become pregnant. It is not known if SYLVANT will harm your unborn baby. You should not become pregnant while receiving treatment with SYLVANT. Females who are able to become pregnant should use effective birth control during treatment with SYLVANT and for 3 months after stopping treatment.
  • are breastfeeding or plan to breastfeed. It is not known if SYLVANT passes into your breast milk. You and your healthcare provider should decide if you will take SYLVANT or breastfeed. You should not do both.Tell your healthcare provider about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of SYLVANT?

SYLVANT may cause serious side effects, including:

  • Infections. SYLVANT may lower your ability to fight infections. Tell your healthcare provider right away if you have any signs or symptoms of an infection during treatment with SYLVANT.
  • Infusion and allergic reactions. If you have an infusion or allergic reaction while receiving SYLVANT, your healthcare provider will stop your infusion and treat your reaction. If you have a severe infusion or allergic reaction, your healthcare provider may stop your treatment completely. Tell your healthcare provider or get medical help right away if you have any of these symptoms during or after your infusion of SYLVANT: back pain, chest pain or tightness, nausea and vomiting, flushing, redness, irregular heart beat (palpitations), trouble breathing, wheezing, dizziness or light-headedness, swelling of the lips, skin rash, headache, or itching.
  • The most common side effects of SYLVANT include rash, itching, upper respiratory tract infection, swelling, weight gain, and increased blood level of uric acid.

These are not all the possible side effects of SYLVANT. Call your HCP for medical advice about side effects. You are encouraged to report side effects of prescription drugs to the FDA. Call 1-800-FDA-1088 or visit www.fda.gov/medwatch.

SYLVANT® (siltuximab) for injection, for intravenous use, is available as 100 mg or 400 mg of lyophilized powder in a single-dose vial.

Please see full Prescribing Information, including Patient Information.

What is SYLVANT?

SYLVANT® (siltuximab) is a prescription medicine used to treat people with multicentric Castleman’s disease (MCD) who do not have human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8) infection. It is not known if SYLVANT is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Who should not receive SYLVANT?

Do not receive SYLVANT if you have had a severe allergic reaction to siltuximab or any of the ingredients in SYLVANT. See the Patient Information leaflet for SYLVANT for a complete list of ingredients.